Coronavirus: FDA to announce emergency use of experimental drug remdesivir after ‘very optimistic’ study
Trials of drug remdesivir show that it appears to shorten recovery time from Covid-19 by one third
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Food and Drug Administration (FDA) plans to authorise the emergency use of remdesivir to treat those infected with the coronavirus.
The experimental antiviral drug is being tested on patients as a treatment for Covid-19.
Both Dr Anthony Fauci and President Donald Trump have expressed optimism about early results from the trials, which show that it shortens recovery time for some patients suffering from the virus. Dr Fauci described the trial results as “very optimistic.”
Dr Fauci, who oversees the National Institute of Allergy and Infectious Diseases (NIAID), cautions that results of their study need to be peer reviewed, but remains positive on the implications of the trial, as remdesivir appears to shorten recovery time by just under a third.
Manufactured by Gilead Sciences, the drug was developed to fight Ebola, but a clinical trial failed to yield results necessary for approval as a treatment.
Gilead’s own study using the drug to treat Covid-19 looked at 397 patients with severe infections taking the drug over five and 10-day courses and found that more than half were discharged from hospital within 14 days.
The company said on Wednesday it was “aware of positive data emerging” in the NIAID study overseen by Dr Fauci, that “met its main goal.”
Dr Fauci said: “Although a 31 per cent improvement doesn’t seem like a knockout 100 per cent, it is a very important proof of concept because what it has proven is that a drug can block this virus.”
A third study that was conducted in China was less positive as it questioned the efficacy of the treatment on severely ill patients. That study was incomplete as it lacked enough participants.
Further details are expected in an upcoming briefing later on Wednesday.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments